Lorlatinib

USDailyMed:Lorlatinib AU:D L01ED05(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile 1454846-35-5 71731823 DB12130 32813339 OSP71S83EU D11012 CHEBI:143117 DTXSID201027944 Interactive image C[C@H]1Oc2cc(cnc2N)c3c(CN(C)C(=O)c4ccc(F)cc14)nn(C)c3C#N InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1Key:IIXWYSCJSQVBQM-LLVKDONJSA-N Lorlatinib, sold under the brand nameLorbrenain the United States, Canada, and Japan, andLorviquain the European Union, is ananti-cancer medicationused for the treatment ofnon-small cell lung cancer.It is an orally administered inhibitor ofanaplastic lymphoma kinase(ALK) andC-ros oncogene 1(ROS1), two enzymes that play a role in the development of cancer.It was developed byPfizer. The most common adverse reactions include edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough. Lorlatinib was approved for medical use in the United States in November 2018,and in the European Union in May 2019.